Published in English - already published 11:18 CET today Disclosure notice in SynAct Pharma AB
SynAct Pharma AB (“SynAct” or the “Company”) hereby announces that the Company’s shareholders TJ Biotech ApS (wholly-owned by the board member and CSO Thomas Jonassen) and Quantass ApS (owned by the CEO Jeppe Øvlesen and his wife Ghita Øvlesen) have carried out a corporate restructuring whereby the companies' holdings of shares in SynAct have been transferred through a merger to the newly formed company BioInvest ApS.Prior to the restructuring, TJ Biotech ApS held 2,296,651 shares, corresponding to approximately 9.41 per cent of the number of shares and votes in the Company, and Quantass